Cardiovascular preventive role of thiazolidinedione in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention
4 affiliations
- 1Department of Neurology Yongin Severance Hospital Yongin South Korea
- 2Department of Neurology Yonsei University College of Medicine Seoul South Korea
- 3Department of Biomedical Systems Informatics Yonsei University College of Medicine Seoul South Korea
- 4Division of Cardiology, Department of Internal Medicine Yonsei University College of Medicine, Yongin Severance Hospital Yongin South Korea
Abstract
Background Thiazolidinediones (TZD) are a class of oral antidiabetic medications that improve glycemic control and insulin sensitivity. We evaluated the cardiovascular outcomes according to thiazolidinedione (TZD) use in patients with type 2 diabetes mellitus (T2DM) undergoing percutaneous coronary intervention (PCI). Methods Using the national health claims database in South Korea, we constructed a cohort of type 2 diabetes mellitus patients who underwent PCI between 2015 and 2022. Patients were classified as TZD users or nonusers and matched at a 1:3 ratio using propensity score matching. Stratified Cox regression analysis was performed to evaluate the risk for the primary composite outcome, which included myocardial infarction (MI), stroke, and all‐cause death. Results Among 169,747 patients with type 2 diabetes mellitus who underwent PCI, 7.4% were TZD users. During a mean follow‐up of 3.63 ± 2.30 years, 31,813 patients (18.7%) experienced the primary outcome. In the stratified Cox regression analysis, which consisted of 12,597 TZD users and 37,791 nonusers, TZD treatment was associated with a lower risk of primary outcome (HR 0.87, 95% CI: 0.83–0.92, P < 0.001). No difference was observed in the risk of heart failure admission between TZD nonusers and users. Conclusions TZD treatment in type 2 diabetes mellitus patients undergoing PCI was associated with a reduced risk of adverse cardiovascular events.
Related
- Triglyceride-glucose index and risk of major adverse cardiovascular events in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention
- Combined Triglyceride–High-density Lipoprotein Cholesterol Phenotypes and Cardiovascular Outcomes in Japanese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights from Clinical Deep Data Accumulation System-PCI
- Prognostic value of the apelin-12-to-white blood cell ratio for long-term major adverse cardiovascular events in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a retrospective cohort study.
- Association Between Admission Calculated Serum Osmolality and New-Onset Atrial Fibrillation in Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
- Guided P2Y12 inhibitor selection after rapid CYP2C19 genotyping in patients undergoing percutaneous coronary intervention
BibTeX
@article{kim2026cardiovascular,
title = {{Cardiovascular preventive role of thiazolidinedione in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention}},
author = {Jinkwon Kim and Jimin Jeon and Joonsang Yoo and Minyoul Baik and Seok‐Jae Heo and Ji Woong Roh},
journal = {Journal of Diabetes Investigation},
year = {2026},
month = nov,
doi = {10.1111/jdi.70385},
url = {https://doi.org/10.1111/jdi.70385},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cardiovascular preventive role of thiazolidinedione in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention
AU - Jinkwon Kim
AU - Jimin Jeon
AU - Joonsang Yoo
AU - Minyoul Baik
AU - Seok‐Jae Heo
AU - Ji Woong Roh
PY - 2026
DA - 2026/11/02
JO - Journal of Diabetes Investigation
DO - 10.1111/jdi.70385
UR - https://doi.org/10.1111/jdi.70385
AB - Background Thiazolidinediones (TZD) are a class of oral antidiabetic medications that improve glycemic control and insulin sensitivity. We evaluated the cardiovascular outcomes according to thiazolidinedione (TZD) use in patients with type 2 diabetes mellitus (T2DM) undergoing percutaneous coronary intervention (PCI). Methods Using the national health claims database in South Korea, we constructed a cohort of type 2 diabetes mellitus patients who underwent PCI between 2015 and 2022. Patients were classified as TZD users or nonusers and matched at a 1:3 ratio using propensity score matching. Stratified Cox regression analysis was performed to evaluate the risk for the primary composite outcome, which included myocardial infarction (MI), stroke, and all‐cause death. Results Among 169,747 patients with type 2 diabetes mellitus who underwent PCI, 7.4% were TZD users. During a mean follow‐up of 3.63 ± 2.30 years, 31,813 patients (18.7%) experienced the primary outcome. In the stratified Cox regression analysis, which consisted of 12,597 TZD users and 37,791 nonusers, TZD treatment was associated with a lower risk of primary outcome (HR 0.87, 95% CI: 0.83–0.92, P < 0.001). No difference was observed in the risk of heart failure admission between TZD nonusers and users. Conclusions TZD treatment in type 2 diabetes mellitus patients undergoing PCI was associated with a reduced risk of adverse cardiovascular events.
SN - 2040-1124
SN - 2040-1116
ER -